BRAF and melanoma: In addition, several studies support the notion that MAPK inhibitor treatment in BRAF mutant melanoma actually promotes the reprogramming of melanoma cells towards a CAF/myofibroblast-like phenotype that is a source of drug resistance and tumor progression (Figure 3).